Several studies have yielded results to suggest that the development of drug resistance during CRC treatment is primarily associated with genetic and epigenetic changes, such as the acquisition of p53 mutations, overexpression of the anti-apoptotic protein Bcl-2, and Bcl-XL, and alterations in transport-based cellular mechanisms 29-31. This evidence concerns the gene BCL2L1 and colorectal carcinoma.